Custom-Made vaccine takes on untreated leukemia in early trial
NCT ID NCT03219450
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a personalized neoantigen vaccine (NeoVax) in 15 people with untreated chronic lymphocytic leukemia (CLL) who have a specific genetic marker (IGHV unmutated). The vaccine is designed to train the immune system to attack each person's unique cancer cells. Some participants also receive low-dose cyclophosphamide or pembrolizumab to boost the immune response. The main goals are to see if the vaccine can be made in time and if it is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Personalized neoantigen vaccine (NeoVax) with or without low-dose cyclophosphamide or pembrolizumab
- What this could lead to
- If successful, this could point toward a new way to control CLL without immediate chemotherapy, using the body's own immune system.
- What could go wrong
- This is a very early, small Phase 1 trial with only 15 people. The main goal is safety and feasibility, not yet effectiveness. The vaccine is personalized, which is complex and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?